title: Positive cone biopsy specimen margins in women infected with the human immunodeficiency virus.
abstract: OBJECTIVE
  The purpose of this study was to compare the positive margin rate associated with cervical conization among women who are seropositive for human immunodeficiency virus with that among women who are seronegative.
  
  
  METHODS
  This was a cross-sectional study of 245 women who underwent cervical conization for the following indications: biopsy-proven cervical intraepithelial neoplasia grade 2 or 3, abnormal endocervical curettage specimen, cytologic-histologic examination discrepancy, persistent cervical intraepithelial neoplasia grade 1, or abnormal cytologic characteristics with inadequate colposcopic examination.
  
  
  RESULTS
  Twenty-two (47.8%) of 46 women who were seropositive for human immunodeficiency virus and 65 (32.7%) of 199 women who were seronegative had positive cone biopsy specimen margins. In a multivariable logistic regression the human immunodeficiency virus-seropositive women had a 2-fold increased risk of having a positive cone biopsy margin (odds ratio, 2.25; 95% confidence interval, 1.07-4.76).
  
  
  CONCLUSIONS
  If the presence of positive cone biopsy specimen margins represents the potential for disease progression, then our findings of a positive margin rate of nearly 50% in a human immunodeficiency virus-positive population may argue against the kind of conservative management of colposcopic follow-up that has been proposed for immunocompetent women.
authors.affiliation: Department of Obstetrics and Gynecology, Women and Infants' Hospital of Rhode Island, Providence 02905, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Boardman
authors.forename: J F
authors.initials: JF
authors.lastname: Peipert
authors.forename: J W
authors.initials: JW
authors.lastname: Hogan
authors.forename: A S
authors.initials: AS
authors.lastname: Cooper
mesh_terms: D000328:Adult; D002584:Cervix Uteri / Q000473:pathology* / Q000601:surgery; D019092:Conization / Q000592:standards*; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005260:Female; D006679:HIV Seropositivity / Q000150:complications*; D006801:Humans; D011237:Predictive Value of Tests; D002583:Uterine Cervical Neoplasms / Q000150:complications / Q000473:pathology* / Q000601:surgery; D002578:Uterine Cervical Dysplasia / Q000150:complications / Q000473:pathology* / Q000601:surgery